SCYX Q4 2020 Earnings — SCYNEXIS, Inc. Revenue & Financial Results | Market Cap Arena

SCYXSCYNEXIS, Inc.

$37M

Q4 2020 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$15M

Net Income

-$43M

EPS (Diluted)

$-4.02

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$17M

Free Cash Flow

-$17M

Stock-Based Comp.

$1M

Balance Sheet

Total Assets

$103M

Total Liabilities

$80M

Stockholders' Equity

$23M

Cash & Equivalents

$93M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$15M	-$14M	-8.7%
Net Income	-$43M	-$14M	-195.4%